Table 4.
Best overall response in patients receiving brigimadlin monotherapy
| D1q3w (n = 29) | D1D8q4w (n = 25) | All patients (N = 54) | |
|---|---|---|---|
| Total treated, n | 29 | 25 | 54 |
| Confirmed objective response, n (%) | 4 (13.8) | 2 (8.0) | 6 (11.1) |
| Complete response, n (%) | 0 | 0 | 0 |
| Partial response, n (%) | 4 (13.8) | 2 (8.0) | 6 (11.1) |
| Stable disease, n (%) | 18 (62.1) | 16 (64.0) | 34 (63.0) |
| Progressive disease, n (%) | 6 (20.7) | 5 (20.0) | 11 (20.4) |
| Not evaluable, n (%) | 1 (3.4) | 2 (8.0) | 3 (5.6) |
| Disease control, n (%) | 22 (75.9) | 18 (72.0) | 40 (74.1) |